134 related articles for article (PubMed ID: 12798323)
1. Molecular design, synthesis, and structure-Activity relationships leading to the potent and selective p56(lck) inhibitor BMS-243117.
Das J; Lin J; Moquin RV; Shen Z; Spergel SH; Wityak J; Doweyko AM; DeFex HF; Fang Q; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2003 Jul; 13(13):2145-9. PubMed ID: 12798323
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56(lck) inhibitors.
Das J; Moquin RV; Lin J; Liu C; Doweyko AM; DeFex HF; Fang Q; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC; Wityak J
Bioorg Med Chem Lett; 2003 Aug; 13(15):2587-90. PubMed ID: 12852972
[TBL] [Abstract][Full Text] [Related]
3. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck).
Wityak J; Das J; Moquin RV; Shen Z; Lin J; Chen P; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; Schieven GL; Kanner SB; Barrish JC
Bioorg Med Chem Lett; 2003 Nov; 13(22):4007-10. PubMed ID: 14592495
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
[TBL] [Abstract][Full Text] [Related]
5. Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck).
Chen P; Norris D; Iwanowicz EJ; Spergel SH; Lin J; Gu HH; Shen Z; Wityak J; Lin TA; Pang S; De Fex HF; Pitt S; Shen DR; Doweyko AM; Bassolino DA; Roberge JY; Poss MA; Chen BC; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2002 May; 12(10):1361-4. PubMed ID: 11992777
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency.
Chen P; Iwanowicz EJ; Norris D; Gu HH; Lin J; Moquin RV; Das J; Wityak J; Spergel SH; de Fex H; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2002 Nov; 12(21):3153-6. PubMed ID: 12372522
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-phenylamino-imidazo[4,5-h]isoquinolin-9-ones: a new class of inhibitors of lck kinase.
Snow RJ; Cardozo MG; Morwick TM; Busacca CA; Dong Y; Eckner RJ; Jacober S; Jakes S; Kapadia S; Lukas S; Panzenbeck M; Peet GW; Peterson JD; Prokopowicz AS; Sellati R; Tolbert RM; Tschantz MA; Moss N
J Med Chem; 2002 Aug; 45(16):3394-405. PubMed ID: 12139450
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of peptidomimetic antagonists of p56(lck) SH2 domain.
Hobbs CJ; Bit RA; Cansfield AD; Harris B; Hill CH; Hilyard KL; Kilford IR; Kitas E; Kroehn A; Lovell P; Pole D; Rugman P; Sherborne BS; Smith IE; Vesey DR; Walmsley DL; Whittaker D; Williams G; Wilson F; Banner D; Surgenor A; Borkakoti N
Bioorg Med Chem Lett; 2002 May; 12(10):1365-9. PubMed ID: 11992778
[TBL] [Abstract][Full Text] [Related]
11. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
12. Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): Structure, synthesis, and SAR.
Takayama T; Umemiya H; Amada H; Yabuuchi T; Koami T; Shiozawa F; Oka Y; Takaoka A; Yamaguchi A; Endo M; Sato M
Bioorg Med Chem Lett; 2010 Jan; 20(1):112-6. PubMed ID: 19945867
[TBL] [Abstract][Full Text] [Related]
13. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
Das J; Chen P; Norris D; Padmanabha R; Lin J; Moquin RV; Shen Z; Cook LS; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; McIntyre KW; Shuster DJ; Gillooly KM; Behnia K; Schieven GL; Wityak J; Barrish JC
J Med Chem; 2006 Nov; 49(23):6819-32. PubMed ID: 17154512
[TBL] [Abstract][Full Text] [Related]
14. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR.
Takayama T; Umemiya H; Amada H; Yabuuchi T; Shiozawa F; Katakai H; Takaoka A; Yamaguchi A; Endo M; Sato M
Bioorg Med Chem Lett; 2010 Jan; 20(1):108-11. PubMed ID: 19945869
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
16. 4-thiophenoxy-N-(3,4,5-trialkoxyphenyl)pyrimidine-2-amines as potent and selective inhibitors of the T-cell tyrosine kinase p56lck.
Moffat DF; Allen RA; Rapecki SE; Davis PD; O'Connell J; Hutchings MC; King MA; Boyce BA; Perry MJ
Curr Med Chem; 2004 Mar; 11(6):747-53. PubMed ID: 15032728
[TBL] [Abstract][Full Text] [Related]
17. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
[TBL] [Abstract][Full Text] [Related]
18. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I.
Arnold LD; Calderwood DJ; Dixon RW; Johnston DN; Kamens JS; Munschauer R; Rafferty P; Ratnofsky SE
Bioorg Med Chem Lett; 2000 Oct; 10(19):2167-70. PubMed ID: 11012021
[TBL] [Abstract][Full Text] [Related]
19. SVM model for virtual screening of Lck inhibitors.
Liew CY; Ma XH; Liu X; Yap CW
J Chem Inf Model; 2009 Apr; 49(4):877-85. PubMed ID: 19267483
[TBL] [Abstract][Full Text] [Related]
20. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
Deak HL; Newcomb JR; Nunes JJ; Boucher C; Cheng AC; DiMauro EF; Epstein LF; Gallant P; Hodous BL; Huang X; Lee JH; Patel VF; Schneider S; Turci SM; Zhu X
Bioorg Med Chem Lett; 2008 Feb; 18(3):1172-6. PubMed ID: 18083554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
